Compounder Imprimis Says Its Actions Are Not Unique, Points To FDA Passive Approval

The CEO of leading compounder, Imprimis Pharmaceuticals, tells Inside Health Policy that despite allegations that it is running afoul of multiple federal laws, FDA is aware of the company's actions and almost all compounders are compounding ingredients that have not been greenlighted by FDA and face no enforcement action. Allergan USA is suing Imprimis Pharmaceuticals over allegations that Imprimis is unfairly competing and engaging in false and misleading advertising by manufacturing and selling ophthalmologic products, which Allergan claims...